Browse > Article
http://dx.doi.org/10.3348/kjr.2012.13.2.195

Effects of Arsenic Trioxide on Radiofrequency Ablation of VX2 Liver Tumor: Intraarterial versus Intravenous Administration  

Seong, Nak-Jong (Division of Intervention, Department of Radiology, Seoul National University Bundang Hospital)
Yoon, Chang-Jin (Division of Intervention, Department of Radiology, Seoul National University Bundang Hospital)
Kang, Sung-Gwon (Division of Intervention, Department of Radiology, Seoul National University Bundang Hospital)
Chung, Jin-Wook (Department of Radiology, Seoul National University College of Medicine, Institute of Radiation Medicine, Seoul National University Medical Research Center, and Clinical Research Institute, Seoul National University Hospital)
Kim, Hyo-Cheol (Department of Radiology, Seoul National University College of Medicine, Institute of Radiation Medicine, Seoul National University Medical Research Center, and Clinical Research Institute, Seoul National University Hospital)
Park, Jae-Hyung (Department of Radiology, Seoul National University College of Medicine, Institute of Radiation Medicine, Seoul National University Medical Research Center, and Clinical Research Institute, Seoul National University Hospital)
Publication Information
Korean Journal of Radiology / v.13, no.2, 2012 , pp. 195-201 More about this Journal
Abstract
Objective: Arsenic trioxide ($As_{2}O_{3}$) can be used as a possible pharmaceutical alternative that augments radiofrequency (RF) ablation by reducing tumor blood flow. The aim of this study was to assess the effect of intraarterial and intravenous administration of $As_{2}O_{3}$ on RF-induced ablation in an experimentally induced liver tumor. Materials and Methods: VX2 carcinoma was grown in the livers of 30 rabbits. $As_{2}O_{3}$ (1 mg/kg) was administered through the hepatic artery (n = 10, group A) or ear vein (n = 10, group B), 30 minutes before RF ablation (125 mA ${\pm}$ 35; 90 ${\pm}$ $5^{\circ}C$). As a control group, 10 rabbits were treated with RF ablation alone (group C). RF was intentionally applied to the peripheral margin of the tumor so that ablation can cover the tumor and adjacent hepatic parenchyma. Ablation areas of the tumor and adjacent parenchymal changes among three groups were compared by the Kruskal-Wallis and Mann-Whitney U test. Results: The overall ablation areas were 156 ${\pm}$ 28.9 $mm^{2}$ (group A), 119 ${\pm}$ 31.7 (group B), and 92 ${\pm}$ 17.4 (group C, p < 0.04). The ablation area of the tumor was significantly larger in group A (73 ${\pm}$ 19.7 $mm^{2}$) than both group B (50 ${\pm}$ 19.4, p = 0.02) and group C (28 ${\pm}$ 2.2, p < 0.01). The ratios of the tumoral ablation area to the overall ablation area were larger in group A (47 ${\pm}$ 10.5%) than that of the other groups (42 ${\pm}$ 7.3% in group B and 32 ${\pm}$ 5.6% in group C) (p < 0.03). Conclusion: Radiofrequency-induced ablation area can be increased with intraarterial or intravenous administration of $As_{2}O_{3}$. The intraarterial administration of $As_{2}O_{3}$ seems to be helpful for the selective ablation of the tumor.
Keywords
Arsenic trioxide; Radiofrequency ablation; Pharmacologic modulation; Chemotherapy; Experimental study;
Citations & Related Records

Times Cited By Web Of Science : 2  (Related Records In Web of Science)
연도 인용수 순위
  • Reference
1 Liu B, Pan S, Dong X, Qiao H, Jiang H, Krissansen GW, et al. Opposing effects of arsenic trioxide on hepatocellular carcinomas in mice. Cancer Sci 2006;97:675-681   DOI   ScienceOn
2 Wang SS, Zhang T, Wang XL, Hong L, Qi QH. Effect of arsenic trioxide on rat hepatocellular carcinoma and its renal cytotoxity. World J Gastroenterol 2003;9:930-935   DOI
3 Lencioni R, Crocetti L. Image-guided thermal ablation of hepatocellular carcinoma. Crit Rev Oncol Hematol 2008;66:200-207   DOI   ScienceOn
4 Livraghi T, Meloni F, Di Stasi M, Rolle E, Solbiati L, Tinelli C, et al. Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: is resection still the treatment of choice? Hepatology 2008;47:82-89
5 Solbiati L, Ierace T, Tonolini M, Osti V, Cova L. Radiofrequency thermal ablation of hepatic metastases. Eur J Ultrasound 2001;13:149-158   DOI   ScienceOn
6 Goldberg SN, Hahn PF, Tanabe KK, Mueller PR, Schima W, Athanasoulis CA, et al. Percutaneous radiofrequency tissue ablation: does perfusion-mediated tissue cooling limit coagulation necrosis? J Vasc Interv Radiol 1998;9:101-111   DOI   ScienceOn
7 Rossi S, Garbagnati F, Lencioni R, Allgaier HP, Marchiano A, Fornari F, et al. Percutaneous radio-frequency thermal ablation of nonresectable hepatocellular carcinoma after occlusion of tumor blood supply. Radiology 2000;217:119-126   DOI
8 Buscarini L, Buscarini E, Di Stasi M, Quaretti P, Zangrandi A. Percutaneous radiofrequency thermal ablation combined with transcatheter arterial embolization in the treatment of large hepatocellular carcinoma. Ultraschall Med 1999;20:47-53   DOI   ScienceOn
9 McGahan JP, Gu WZ, Brock JM, Tesluk H, Jones CD. Hepatic ablation using bipolar radiofrequency electrocautery. Acad Radiol 1996;3:418-422   DOI   ScienceOn
10 Livraghi T, Goldberg SN, Monti F, Bizzini A, Lazzaroni S, Meloni F, et al. Saline-enhanced radio-frequency tissue ablation in the treatment of liver metastases. Radiology 1997;202:205-210   DOI
11 Horkan C, Ahmed M, Liu Z, Gazelle GS, Solazzo SA, Kruskal JB, et al. Radiofrequency ablation: effect of pharmacologic modulation of hepatic and renal blood flow on coagulation diameter in a VX2 tumor model. J Vasc Interv Radiol 2004;15:269-274   DOI   ScienceOn
12 Waxman S, Anderson KC. History of the development of arsenic derivatives in cancer therapy. Oncologist 2001;6 Suppl 2:3-10
13 Murgo AJ. Clinical trials of arsenic trioxide in hematologic and solid tumors: overview of the National Cancer Institute Cooperative Research and Development Studies. Oncologist 2001;6 Suppl 2:22-28
14 Tamm I, Paternostro G, Zapata JM. Treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 1999;340:1043; author reply 1044-1045   DOI   ScienceOn
15 Tan B, Huang JF, Wei Q, Zhang H, Ni RZ. Anti-hepatoma effect of arsenic trioxide on experimental liver cancer induced by 2-acetamidofluorene in rats. World J Gastroenterol 2005;11:5938-5943   DOI
16 Xu HY, Yang YL, Liu SM, Bi L, Chen SX. Effect of arsenic trioxide on human hepatocarcinoma in nude mice. World J Gastroenterol 2004;10:3677-3679   DOI
17 Griffin RJ, Monzen H, Williams BW, Park H, Lee SH, Song CW. Arsenic trioxide induces selective tumour vascular damage via oxidative stress and increases thermosensitivity of tumours. Int J Hyperthermia 2003;19:575-589   DOI   ScienceOn
18 Hakime A, Hines-Peralta A, Peddi H, Atkins MB, Sukhatme VP,Signoretti S, et al. Combination of radiofrequency ablation with antiangiogenic therapy for tumor ablation efficacy: study in mice. Radiology 2007;244:464-470   DOI   ScienceOn
19 Monzen H, Griffin RJ, Williams BW, Amano M, Ando S, Hasegawa T. Study of arsenic trioxide-induced vascular shutdown and enhancement with radiation in solid tumor. Radiat Med 2004;22:205-211
20 Hines-Peralta A, Sukhatme V, Regan M, Signoretti S, Liu ZJ, Goldberg SN. Improved tumor destruction with arsenic trioxide and radiofrequency ablation in three animal models. Radiology 2006;240:82-89   DOI   ScienceOn
21 Sze DY, Freeman SM, Slonim SM, Samuels SL, Andrews JC, Hicks M, et al. Dr. Gary J. Becker Young Investigator Award: intraarterial adenovirus for metastatic gastrointestinal cancer: activity, radiographic response, and survival. J Vasc Interv Radiol 2003;14:279-290   DOI   ScienceOn
22 Hohn DC, Stagg RJ, Friedman MA, Hannigan JF Jr, Rayner A, Ignoffo RJ, et al. A randomized trial of continuous intravenous versus hepatic intraarterial floxuridine in patients with colorectal cancer metastatic to the liver: the Northern California Oncology Group trial. J Clin Oncol 1989;7:1646- 1654   DOI
23 Institute of Laboratory Animal Resources Committee on Revision of the Guide for Laboratory Animals Facilities and Care of the Institute of Laboratory Animal Resources National Research Council, 3rd revised ed, 1968. Guide for laboratory animal facilities and care. Washington, DC: U.S. Public Health Service Publication No. 1024, 19681968
24 Lew YS, Brown SL, Griffin RJ, Song CW, Kim JH. Arsenic trioxide causes selective necrosis in solid murine tumors by vascular shutdown. Cancer Res 1999;59:6033-6037
25 Roboz GJ, Dias S, Lam G, Lane WJ, Soignet SL, Warrell RP Jr, et al. Arsenic trioxide induces dose- and time-dependent apoptosis of endothelium and may exert an antileukemic effect via inhibition of angiogenesis. Blood 2000;96:1525- 1530
26 Kemeny N, Fata F. Hepatic-arterial chemotherapy. Lancet Oncol 2001;2:418-428   DOI   ScienceOn
27 Lin CJ, Wu MH, Hsueh YM, Sun SS, Cheng AL. Tissue distribution of arsenic species in rabbits after single and multiple parenteral administration of arsenic trioxide: tissue accumulation and the reversibility after washout are tissueselective. Cancer Chemother Pharmacol 2005;55:170-178   DOI   ScienceOn